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In the article above, we, the authors, discovered that a single microscopy panel was inadvertently 
placed in Figure 1f, using the SEBTA-023 panel twice instead of the SEBTA-003 representative 
image. We discovered that an actin western blot loading control data associated with Figure 3a was 
also incorrectly placed in Figure 5i. We retrieved the original actin western blot data linked to Figure 
5i and corrected this error. 
 
Neither correction alter the conclusions of the original paper; however, we 
sincerely apologize for any confusion that this may have caused. 
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